Advertisement · 728 × 90
#
Hashtag
#TNFA
Advertisement · 728 × 90
JANITORS
PLAYERS TO WATCH

Alex Fops
QB - 4
Won Normal Bowl III with Hellcats, still released. Expected to make big plays with Sitler and Morris.

Hugh Morris
TE - 85
Drafted 7th overall in the first round. Expected to make an immediate impact on offense.

R.J. Scamptapper
MLB - 54
Run stopping general on Janitor's defense - led preseason stats in total tackles.

Ari DiVelcoro
CB - 26
Preseaosn QB prospect turned defensive back. Important matchup covering Frank Mellonballer.

JANITORS PLAYERS TO WATCH Alex Fops QB - 4 Won Normal Bowl III with Hellcats, still released. Expected to make big plays with Sitler and Morris. Hugh Morris TE - 85 Drafted 7th overall in the first round. Expected to make an immediate impact on offense. R.J. Scamptapper MLB - 54 Run stopping general on Janitor's defense - led preseason stats in total tackles. Ari DiVelcoro CB - 26 Preseaosn QB prospect turned defensive back. Important matchup covering Frank Mellonballer.

STOATS
PLAYERS TO WATCH

Jay Powers
QB - 1
Backup defensive tackle given the starting QB role. A complete unknown.

Terry Shutcrunch
RB - 34
Beloved Trash Pandas strong safety now the Stoat's big rushing threat. 6.9yd average in preseason.

Slim Juggins Jr.
WR - 19
Drafted 5th overall in the first round. Brings much needed depth to the Stoat's WR core.

Frank Mellonballer
WR - 11
The Stoat's #1 weapon. Consistently makes huge plays in big moments.

STOATS PLAYERS TO WATCH Jay Powers QB - 1 Backup defensive tackle given the starting QB role. A complete unknown. Terry Shutcrunch RB - 34 Beloved Trash Pandas strong safety now the Stoat's big rushing threat. 6.9yd average in preseason. Slim Juggins Jr. WR - 19 Drafted 5th overall in the first round. Brings much needed depth to the Stoat's WR core. Frank Mellonballer WR - 11 The Stoat's #1 weapon. Consistently makes huge plays in big moments.

HELLCATS
PLAYERS TO WATCH

Ash McEnrowe
QB - 5
Won Normal Bowl II with the Beefers. Replacing the ousted Fops after an INT filled season.

Ace Deucy
RB - 22
Insane Season 3 rushing average earning him MVP. Offensive line improvements will make him even better.

Andy Overnight
WR - 8
Part of the Shitbirds' legendary passing offense in Season 1. Hasn't broken out in recent seasons.

Scott Kernelpop
MLB - 57
Season 3 Defensive Player of the Season. Can go seemingly invisible covering the middle of the field. Gator's Public Enemy #1.

HELLCATS PLAYERS TO WATCH Ash McEnrowe QB - 5 Won Normal Bowl II with the Beefers. Replacing the ousted Fops after an INT filled season. Ace Deucy RB - 22 Insane Season 3 rushing average earning him MVP. Offensive line improvements will make him even better. Andy Overnight WR - 8 Part of the Shitbirds' legendary passing offense in Season 1. Hasn't broken out in recent seasons. Scott Kernelpop MLB - 57 Season 3 Defensive Player of the Season. Can go seemingly invisible covering the middle of the field. Gator's Public Enemy #1.

GATORS
PLAYERS TO WATCH

Geoff Fourshot
QB - 4
QB for the Rollers' Normal Bowl team in Season 2. Interception prone. Was not on a roster for Season 3.

Ken McStoat
WR - 19
The "right hand" of the passing attack. 3rd most receiving yards in Season 3 (704).

Will Terpin
S - 0
Drafted 10th overall in the 2nd round. A be-anywhere strong safety that the team built their defense around.

GATORS PLAYERS TO WATCH Geoff Fourshot QB - 4 QB for the Rollers' Normal Bowl team in Season 2. Interception prone. Was not on a roster for Season 3. Ken McStoat WR - 19 The "right hand" of the passing attack. 3rd most receiving yards in Season 3 (704). Will Terpin S - 0 Drafted 10th overall in the 2nd round. A be-anywhere strong safety that the team built their defense around.

In order to help put faces to the names of the #TNFA, I'm including a player spotlight segment on the preshow. Let me know what you think of the layout and I'll try to improve it.

5 0 0 0
Preview
Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol “QCLS” Q/C Technologies (Nasdaq: QCLS), formerly TNF Pharmaceuticals (Nasdaq: TNFA), has begun trading under its new ticker symbol "QCLS" on the Nasdaq. The company's rebranding reflects its strategic pivot from pharmaceuticals to quantum-class computing, specifically focusing on cryptocurrency applications.The company has secured exclusive global rights to LightSolver's light-speed laser processing unit (LPU), positioning itself as a pioneer in light and laser-based computing systems. Executive Chairman Joshua Silverman emphasized this transition as a significant milestone in aligning the company's public identity with its new technological direction.

#QCLS #TNFA Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol “QCLS”

www.stocktitan.net/news/QCLS/q-c-technologi...

0 0 0 0

NEWS: ( NASDAQ: #TNFA ) TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol "QCLS" to Reflect Strategic Focus on Quantum Class Photonic Computing

0 0 0 0
Most Searched, Wednesday September 24, 2025 – Crystal Equity Research

Most searched small-cap stocks, Wed Sept 24th - #RCAT #IDAI #WOLF #SHFS #EOSE #CDLX #RXRX #SLNH #ONDS #RR #IAS #HIVE #TNFA #QURE #BITF #DNN #PLUG #SBET #LAC #LAES - More: crystalequityresearch.com/most-searche... - #smallcap

1 0 0 0
Preview
TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol “QCLS” to Reflect Strategic Focus on Quantum Class Photonic Computing TNF Pharmaceuticals (NASDAQ:TNFA) announced its corporate rebranding to Q/C Technologies and will trade under the new ticker symbol QCLS effective September 25, 2025. The name change reflects the company's strategic pivot from pharmaceuticals to quantum-class computing, following its acquisition of exclusive global rights to LightSolver's light-speed laser processing unit (LPU) for cryptocurrency applications.The LPU technology offers significant advantages including 90% reduction in energy consumption compared to traditional systems while delivering superior performance to both GPUs and quantum computing. The company will continue evaluating strategic options for its legacy therapeutic programs, isomyosamine and Supera-CBD, as it transitions into blockchain infrastructure.

#TNFA TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol “QCLS” to Reflect Strategic Focus on Quantum Class Photonic Computing

www.stocktitan.net/news/TNFA/tnf-pharmaceut...

0 0 0 0
Preview
TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications TNF Pharmaceuticals (Nasdaq: TNFA) has secured exclusive global rights to LightSolver's innovative laser-based processing unit (LPU) technology for cryptocurrency applications. The groundbreaking light-based computing system is designed to outperform quantum and supercomputing while reducing energy costs by up to 90%.LightSolver, recognized as a 2025 World Economic Forum Technology Pioneer, has developed quantum-inspired LPU-based systems that operate at the speed of light. The company has also secured a $7 million private placement financing from strategic investors, with preferred stock convertible at $5.00 per share and accompanying five-year warrants.TNF plans to rebrand to reflect its new strategic direction while continuing to evaluate options for its legacy therapeutic platforms.

#TNFA TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications

www.stocktitan.net/news/TNFA/tnf-pharmaceut...

0 0 0 0
Preview
TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance TNF Pharmaceuticals (Nasdaq: TNFA), a clinical-stage biopharmaceutical company, has announced a 1-for-100 reverse stock split effective September 2, 2025. The split will reduce outstanding shares from 178,615,658 to 1,786,157.The reverse split will maintain the stock's $0.001 par value, with fractional shares being rounded up. Proportional adjustments will be made to equity awards, convertible preferred stock, warrants, and other convertible securities. The company's new CUSIP number will be 62856X300.This corporate action appears aimed at regaining Nasdaq listing compliance, with operational business updates expected to coincide with the split completion.

#TNFA TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance

www.stocktitan.net/news/TNFA/tnf-pharmaceut...

0 0 0 0
Preview
$17M Assets Maintained: TNF Pharmaceuticals Announces Major Debt Reduction and Growth Strategy Shift Clinical stage biotech TNF Pharmaceuticals strengthens financial position through liability reduction while maintaining $17M in assets. Advances Renova collaboration on GLP inflammation research.

#TNFA TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation

www.stocktitan.net/news/TNFA/tnf-pharmaceut...

0 0 0 0
Preview
TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease TNF Pharmaceuticals (Nasdaq: TNFA) has announced a philanthropic collaboration with the DADA2 Foundation to initiate a Compassionate Use study of their lead candidate isomyosamine for treating DADA2, a rare pediatric autoinflammatory disease.DADA2 is characterized by systemic inflammation, vasculitis, early-onset stroke, and other severe complications, primarily affecting children. While biological TNF inhibitors are currently the only effective treatment, isomyosamine offers potential advantages as an orally administered small molecule TNF-alpha inhibitor with comparable potency and minimal immunosuppression.The disease affects over 600 known patients, with research suggesting up to 35,000 undiagnosed cases globally. About 25% of patients are diagnosed before age one, and 77% by age ten.

#TNFA TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

www.stocktitan.net/news/TNFA/tnf-pharmaceut...

1 0 0 0
Preview
TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists TNF Pharmaceuticals (NASDAQ: TNFA) and Renova Health have announced positive results from their initial study analyzing 30,000 patients receiving GLP-1 agonists like Wegovy® or Ozempic®. The study aims to evaluate the potential of TNF's oral drug isomyosamine in preserving lean muscle mass during GLP-1 treatment for weight loss.The research identified patient convergences between GLP-1 agonist use and inflammation-linked chronic disorders. Initial findings revealed that conditions like sarcopenia and frailty are underreported compared to CDC estimates, suggesting at-risk populations might experience adverse events from GLP-1 treatment without proper surveillance for muscle wasting. The data will be used to optimize patient recruitment and accelerate isomyosamine's development.

#TNFA TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists

www.stocktitan.net/news/TNFA/tnf-pharmaceut...

0 0 0 0
Preview
Revolutionary AI Analysis of 30,000 Patients Tackles Major GLP-1 Side Effect: Muscle Loss Prevention Advanced AI platform analyzes 30,000 patient records to revolutionize muscle preservation during GLP-1 treatment. See how this breakthrough targets high-risk groups.

#TNFA TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

www.stocktitan.net/news/TNFA/tnf-pharmaceut...

0 0 0 0
Preview
Breakthrough Oral Treatment for Muscle Loss: TNF Pharma Reports Positive Clinical Data Novel oral TNF-alpha inhibitor isomyosamine shows positive biomarker results in elderly sarcopenia patients, advancing to Phase 2b trial for post-surgery muscle loss treatment.

#TNFA TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia

www.stocktitan.net/news/TNFA/tnf-pharmaceut...

0 0 0 0
Preview
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor TNF Pharmaceuticals (NASDAQ: TNFA) has initiated a Phase 2b clinical trial for isomyosamine, their oral TNF-alpha inhibitor drug candidate, targeting chronic inflammation associated with muscle loss in post-surgical hip/femur fracture patients.The fully funded, randomized, placebo-controlled study at the University of Florida will evaluate 60 patients for up to 90 days post-surgery. The trial builds on previous positive Phase 2a results and aims to explore isomyosamine's efficacy in preventing progressive muscle loss and frailty.Key advantages of isomyosamine include:Oral administration versus current injection/infusion-only optionsSelective TNF-α blocking where overactivatedAbility to cross blood-brain barrierLower risk of serious side effects compared to traditional treatmentsThe target market is substantial:TNF-alpha inhibitor market: $39.7B (2024), expected to reach $47.3B by 2029Sarcopenia affects 10-16% of elderly populationSarcopenia treatment market: $3.07B (2024), projected to reach $4.0B by 2029

#TNFA TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

www.stocktitan.net/news/TNFA/tnf-pharmaceut...

0 0 0 0
Preview
Revolutionary Drug Could Solve the Hidden Problem with Ozempic and Wegovy Weight Loss TNF Pharmaceuticals launches studies of isomyosamine to combat muscle loss in GLP-1 patients, partnering with Renova Health's AI technology to tap into $49.3B market opportunity.

#TNFA TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

www.stocktitan.net/news/TNFA/tnf-pharmaceut...

0 0 0 0

Just In: ( NASDAQ: #TNFA ) TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

0 0 0 0
Preview
TNF Pharma Partners on Breakthrough GLP-1 Muscle Loss Treatment, Eyes $105B Market Opportunity TNF Pharmaceuticals launches groundbreaking study for muscle preservation in GLP-1 patients, targeting massive market need. Could become first therapy for Wegovy-related muscle loss.

#TNFA #MYMD TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

www.stocktitan.net/news/TNFA/tnf-pharmaceut...

0 0 0 0

JUST IN: ( NASDAQ: #TNFA ) TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

#StockMarket #News

0 0 0 0